NHS fat jab gender split revealed after GPs gave 310k Brits slimming injections in just one year
MORE women than men were handed fat jab medicines on the NHS last year. Stats for England show 310,300 got GLP-1 slimming injections from their GP between December 2024 and November 2025. Among them were 163,400 women and 146,900 men, a 53-47 gender split. They were charged £9.90 a month for the prescriptions if not…
5 things to know about GLP-1 use in Medicare: KFF
Participating Medicare Part D plans can officially begin covering weight-loss treatment in 2027. The initiative falls under CMS’ voluntary “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth” — or BALANCE — model. The December news followed President Donald Trump’s negotiations with Eli Lilly and Novo Nordisk to secure most-favored-nation pricing for drugs that treat […]
The Most Stunning Black Celebrity Weight Loss Transformations With GLP-1s!
As more and more of our favorite stars step out with newly slimmed-down physiques, one of the first questions many can’t help but ask is, “Did they, or didn’t they?” use GLP-1 medications that help lower blood sugar levels and reduce hunger to help them shed the pounds. But what was once a secret is […]
29% of employees say they’d switch jobs for GLP-1 coverage, how are you dealing with this?
There were many reports today stating 29% of employees would consider changing jobs if a new role covered GLP-1 meds. Wondering if it’s something that actually impacts retention and hiring especially with costs climbing fast for employers. Are benefits like this already part of your talent strategy, or is salary/comp still carrying most of the […]
CHMP opposes Lilly’s Mounjaro in heart failure, backs Novo’s Kayshild
EU regulators have refused to greenlight Eli Lilly’s weight loss drug Mounjaro as a treatment for a type of heart failure, while giving the go-ahead for Novo Nordisk’s semaglutide in liver disease. Lilly failed to …
First GLP-1 Backed for MASH in Europe
Kayshild is recommended for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis and moderate-to-advanced liver fibrosis. Medscape News Europe
MHRA Warns of Rare Severe Pancreatitis With GLP-1 Drugs
The MHRA has updated safety information for GLP-1 weight-loss and diabetes drugs after rare reports of necrotising and fatal pancreatitis. Medscape News UK
New GLP-1 Weight-Loss Drugs Expected This Year
This Medical News article discusses clinical trial data for weight-loss medications, in both injectable and pill formations, that are currently under review with US Food and Drug Administration.
Bariatric Surgery and GLP-1 Drugs Both Support Sustained Fat Loss
Although bariatric surgery was associated with more evident changes, research found that treatment with glucagon-like peptide-1 (GLP-1) medications was also associated with sustained fat loss in a clinical setting.
FDA Requests Removal of Suicidal Ideation Warning From GLP-1 RA Medications
The US Food and Drug Administration (FDA) requested that drug application holders remove suicidal ideation and behavior warnings from glucagon-like peptide-1 (GLP-1) receptor agonists.